The inclusion of Janssen Biotech Inc.’s Stelara (ustekinumab) and Novo Nordisk A/S’s NovoLog (insulin aspart) in the initial Medicare price negotiation list surprised some observers. Many thought biosimilar competition on the horizon may disqualify them.
A little-known Inflation Reduction Act provision appears to have negated the move, along with the competing biosimilars’ development timelines